Certolizumab Pegol

Brand: Cimzia

Immunomodulator PEGylated anti–TNF-α antibody fragment (Fab’)

Chemistry

PubChem

CID: 16134944
Open in PubChem

Structure

Half-life	14 days
Clearance Route	reticuloendothelial
Active Metabolites	none
Notes	Fab’ fragment without Fc → minimal placental transfer; lower complement activation; same infection risk as other TNF blockers.

Severity: Severe

Adverse Effects:
Infections (TB, invasive fungal), injection reactions, hepatotoxicity, cytopenias, malignancy risk

Contraindications:
Active infections, untreated TB, moderate–severe heart failure

Precautions:
Screen for TB & HBV; avoid live vaccines; monitor CBC & LFTs; caution in demyelinating disorders